Bounc­ing back from a PhII flop in schiz­o­phre­nia, Neu­ro­crine steers in­to the busy M4/M1 path­way with a $100M cash deal

Eight months af­ter Neu­ro­crine $NBIX chron­i­cled a flop for a mid-stage schiz­o­phre­nia drug, the biotech is head­ed right back in­to Phase II armed with a new drug can­di­date from So­sei Hep­tares.

Neu­ro­crine out­lined a deal that pro­vides So­sei Hep­tares $100 mil­lion up­front, R&D ex­pens­es and a moth­er­lode of mile­stones worth up to $2.6 bil­lion if suc­cess­ful. That start­ing fig­ure close­ly re­sem­bles what the biotech paid Take­da to land 3 pro­grams, in­clud­ing the schiz­o­phre­nia drug TAK-831, which failed to mea­sure up in the clin­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER